Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 115

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 115
---
1 n=7, gMFI = 5033; T2 n=8, gMFI = 1873; T3 n=8, gMFI = 611. Of note, the two on-therapy
samples showed high percent and gMFI of cell surface TIM-4-L, with a patient receiving 5-azacytidine showing 1.8 fold TIM-4-L gMFI over
median. The second patient receiving TKI therapy showed 3.3 fold TIM-4-L gMFI over median. Healthy donor samples had much lower cell surface
TIM-4-L, with a mean gMFI of 582. Circulating AML leukemic blasts were also evaluated for cell surface TIM-4-L and showed high concordance
with BM blasts, with high levels of cell surface TIM-4-L compared to healthy donor peripheral blood mononuclear cells (“PBMCs”).

12

Table 1. AML patient characteristics

    Patient:
    Patient ID 
    Treatment
    Status:
     Disease Status 
    Previous
    Treatments 
    Patient
     Age At  Collection 
    Gender 
    Race 
    Patient:
    Ethnicity 
    %
    Blast  Cells 
    Risk
    Category 
    Genetic
     Abnormality 
    Cytogenetics
  
    200001107 
    Newly Diagnosed 
    none 
    67 
    Female 
    White 
    Non-Hispanic/Latino 
    91 
    Adverse 
    RUNX1 
    N/A
  
    200015767 
    Newly Diagnosed 
    none 
    59 
    Female 
    White 
    Non-Hispanic/Latino 
    35 
    Adverse 
    TP53 
    N/A
  
    200013141 
    Newly Diagnosed 
    none 
    69 
    Male 
    White 
    Non-Hispanic/Latino 
    75 
    Intermediate 
    VAF ASXL1 < 50% 
    N/A
  
    200015300 
    Newly Diagnosed 
    none 
    59 
    Male 
    White 
      
    93.03 
      
    N/A 

    200018491 
    Newly Diagnosed 
    none 
    62 
    Female 
    White 
    Non-Hispanic/Lat